FMC Corporation Submits Regulatory Dossier for Rimisoxafen, the Industry's First Dual Mode of Action Herbicide, in Brazil

Formulated-product filings are expected to follow the Brazilian dossier, while regulatory approval remains outstanding.

Rhea-AI Summary

FMC (FMC) submitted a regulatory dossier for its dual-mode herbicide rimisoxafen to Brazilian authorities for review. This is rimisoxafen's second global submission, following a July 2026 filing with the U.S. Environmental Protection Agency. It is the third novel herbicide active ingredient FMC has submitted for review in Brazil. Classified in herbicide Groups 12 and 32, rimisoxafen showed activity in FMC field testing against small-seeded broadleaf weeds, including resistant Amaranthus palmeri and Amaranthus hybridus.

FMC expects formulated-product submissions to follow as review advances. Rimisoxafen is not registered for sale or use in Brazil or any other country; timing and outcomes remain subject to regulatory review and approval.

Positive

• Brazilian dossier submitted, marking rimisoxafen's second global filing after the July 2026 U.S. submission.
• FMC field testing showed consistent activity against small-seeded broadleaf weeds, including resistant Amaranthus palmeri and Amaranthus hybridus.
• Third novel herbicide active ingredient advanced by FMC to regulatory submission in Brazil.
• Formulated-product submissions are expected to follow as Brazil's regulatory process advances.

Negative

• Rimisoxafen remains unregistered for sale or use in Brazil or any other country; timing and outcomes remain subject to regulatory review and approval.

Market Context

FMC's reported $200.0 million prepurchase payment under a rimisoxafen license with Corteva links pri...

Analysis

FMC's reported $200.0 million prepurchase payment under a rimisoxafen license with Corteva links prior platform records to the same active ingredient; this Brazil dossier is a regulatory step, not an approval.

Key Figures

Global regulatory submission: 2nd submission Brazil corn and soybean area: More than 70 million hectares

Global regulatory submission

2nd submission

Brazil dossier, following the U.S. EPA submission in July 2026

Brazil corn and soybean area

More than 70 million hectares

Production area cited in the article as market scope

Key Terms

dual mode of action, glyphosate, acetolactate synthase inhibitors

3 terms

dual mode of action technical

"the first and only dual mode of action herbicide"

Dual mode of action describes a medical product that works through two different biological or physical processes to produce its effect — for example one component may directly target disease-causing agents while the other reduces symptoms or protects tissue. Investors care because two complementary ways of working can make a product more effective, broaden its uses and raise barriers to competitors, but they can also increase development complexity, regulatory scrutiny and costs.

glyphosate technical

"has developed resistance to glyphosate and acetolactate synthase inhibitors"

A broad‑spectrum herbicide used widely to kill weeds and grasses in farming and landscaping; think of it as a powerful weed killer farmers spray to protect crop rows. Investors care because rules, health or environmental concerns, or large lawsuits can change how much farmers use it, alter crop yields and input costs, and affect sales and legal exposure for chemical and agricultural businesses.

acetolactate synthase inhibitors technical

"glyphosate and acetolactate synthase inhibitors"

A class of herbicides that block the plant enzyme acetolactate synthase (ALS), stopping growth by preventing production of certain essential amino acids. They are widely used in crop protection and their effectiveness, regulatory approval, patent status, and the rise of resistant weeds affect the sales, product lifecycles, and risk profile of agricultural chemical companies. Think of them as a targeted switch that shuts down a plant’s internal “factory” for making building blocks it needs to grow.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Second global filing advances rimisoxafen as a novel weed control solution for Brazil's more than 70 million hectares of corn and soybeans

PHILADELPHIA, Sept. 28, 2026 /PRNewswire/ --

FMC Corporation (NYSE: FMC), a leading global agricultural sciences company, today announced the submission of the regulatory dossier for rimisoxafen to Brazilian regulatory authorities. The filing marks the second global regulatory submission for rimisoxafen, the first and only dual mode of action herbicide, following FMC's submission to the U.S. Environmental Protection Agency in July 2026.

Brazil is among the world's largest soybean and corn markets, with approximately 50 million hectares of soybean and over 20 million hectares of corn in production. Growers are facing mounting pressure from resistant broadleaf weeds, including Amaranthus hybridus, which has developed resistance to glyphosate and acetolactate synthase inhibitors, and Amaranthus palmeri, a regulated quarantine weed posing a significant and growing threat to crop productivity.

"Brazilian growers are facing complex weed resistance challenges that demand new and differentiated solutions," said Leonardo Bastos, vice president and chief marketing officer at FMC. "Submitting rimisoxafen for regulatory review in Brazil is an important step forward, demonstrating our long-term commitment to this market and to the growers who depend on innovation to protect their crops and their livelihoods."

Classified by the Herbicide Resistance Action Committee under Groups 12 and 32, rimisoxafen offers growers a novel tool to help diversify weed management programs and support long-term resistance management. In extensive FMC field testing, rimisoxafen has demonstrated consistent activity against small seeded broadleaf weeds and those resistant to other herbicides, including Amaranthus palmeri and Amaranthus hybridus.

Rimisoxafen is the third novel herbicide active ingredient FMC has advanced to regulatory submission in Brazil, following Isoflex™ active and Dodhylex™ active. Together, these submissions reflect the depth and productivity of FMC's research and development pipeline and the company's commitment to advancing next-generation crop protection solutions through the regulatory process.

Formulated product submissions for rimisoxafen are expected to follow as the regulatory process advances in Brazil. Timing and outcomes remain subject to regulatory review and approval. Rimisoxafen is not registered for sale or use in Brazil or any other country. No offer for sale, sale or use of this product is permitted prior to receipt of all required regulatory approvals.

About FMC

FMC Corporation is a global agricultural sciences company dedicated to helping growers produce food, feed, fiber and fuel for an expanding world population while adapting to a changing environment. FMC's innovative crop protection solutions – including biologicals, crop nutrition, digital and precision agriculture – enable growers and crop advisers to address their toughest challenges economically while protecting the environment. FMC is committed to discovering new herbicide, insecticide and fungicide active ingredients, product formulations and pioneering technologies that are consistently better for the planet. Visit fmc.com to learn more and follow us on LinkedIn^®.

Isoflex and Dodhylex are trademarks of FMC Corporation and/or an affiliate. Always read and follow all label directions, restrictions and precautions for use. Products listed here may not be registered for sale or use in all states, countries or jurisdictions.

Statement under the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995:  FMC and its representatives may from time to time make written or oral statements that are "forward-looking" and provide other than historical information, including statements contained in this press release, in FMC's other filings with the SEC, and in presentations, reports or letters to FMC stockholders.

In some cases, FMC has identified these forward-looking statements by such words or phrases as "outlook", "will likely result," "is confident that," "expect," "expects," "should," "could," "may," "will continue to," "believe," "believes," "anticipates," "predicts," "forecasts," "estimates," "projects," "potential," "intends" or similar expressions identifying "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including the negative of those words or phrases. Such forward-looking statements are based on our current views and assumptions regarding future events, future business conditions and the outlook for the company based on currently available information. The forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement. These statements are qualified by reference to the risk factors included in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2025 (the "2025 Form 10-K"), the section captioned "Forward-Looking Information" in Part II of the 2025 Form 10-K and to similar risk factors and cautionary statements in all other reports and forms filed with the Securities and Exchange Commission ("SEC"). We wish to caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made.  Forward-looking statements are qualified in their entirety by the above cautionary statement.

We specifically decline to undertake any obligation, and specifically disclaims any duty, to publicly update or revise any forward-looking statements that have been made to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events, except as may be required by law.

View original content to download multimedia:https://www.prnewswire.com/news-releases/fmc-corporation-submits-regulatory-dossier-for-rimisoxafen-the-industrys-first-dual-mode-of-action-herbicide-in-brazil-302891817.html

SOURCE FMC Corporation

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Is FMC's rimisoxafen approved for sale or use in Brazil?

No. Rimisoxafen is not registered for sale or use in Brazil or any other country. Sale or use is not permitted before all required regulatory approvals are received.